Compare · ABT vs AYTU
ABT vs AYTU
Side-by-side comparison of Abbott Laboratories (ABT) and Aytu BioPharma Inc. (AYTU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AYTU operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.59B, about 7767.9x AYTU ($23.5M).
- Over the past year, ABT is down 20.0% and AYTU is down 4.3% - AYTU leads by 15.7 points.
- ABT has hit the wire 10 times in the past 4 weeks while AYTU has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 2 for AYTU).
- Company
- Abbott Laboratories
- Aytu BioPharma Inc.
- Price
- $105.58-2.49%
- $2.23-0.89%
- Market cap
- $182.59B
- $23.5M
- 1M return
- -2.07%
- -4.29%
- 1Y return
- -20.02%
- -4.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Aytu BioPharma Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest AYTU
- Amendment: SEC Form SCHEDULE 13G/A filed by Aytu BioPharma Inc.
- Chief Commercial Officer Pyszczymuka Greg was granted 20,000 shares, increasing direct ownership by 55% to 56,102 units (SEC Form 4)
- Chief Executive Officer Disbrow Joshua R. was granted 30,000 shares, increasing direct ownership by 14% to 237,203 units (SEC Form 4)
- Chief Business Officer Disbrow Jarrett was granted 15,000 shares, increasing direct ownership by 24% to 76,568 units (SEC Form 4)
- Chief Financial Officer Selhorn Ryan J was granted 25,000 shares, increasing direct ownership by 50% to 74,743 units (SEC Form 4)
- Director Liu Vivian H was granted 10,000 shares, increasing direct ownership by 50% to 29,825 units (SEC Form 4)
- Director Jain Abhinav was granted 10,000 shares, increasing direct ownership by 51% to 29,500 units (SEC Form 4)
- Director Dockery Carl was granted 10,000 shares, increasing direct ownership by 47% to 31,152 units (SEC Form 4)
- Director Donofrio John Jr. was granted 10,000 shares, increasing direct ownership by 73% to 23,762 units (SEC Form 4)
- Aytu BioPharma Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement